Assess genome integrity and off-target events with confidence.
Optical genome mapping (OGM) detects structural variants at a low allele frequency with high resolution to better assess genomic integrity and off-target events in cell and gene therapies. Using a genome-wide, sensitive, and reproducible workflow, OGM delivers results quickly. See the full genomic picture and pave the way for safer therapies that get to market faster.
How OGM worksOGM quick view
Hear from Bionano’s VP of Clinical & Scientific Affairs, Dr. Alex Hastie, about how OGM can transform cell and gene therapy programs.
- Dive into how OGM principles are reshaping cell and gene therapy R&D.
- Understand OGM’s pivotal role in precise genetic modification assessments.
- Explore OGM’s applications in genome integrity and off-target analysis.
Cell & gene therapy expert insights
Dr. Jeanne Loring: Unveiling the Promise of iPSCs in Therapy Research & Development with Optical Genome Mapping
- Discover Dr. Jeanne Loring’s groundbreaking iPSC research and its promise for treating Parkinson’s disease at Aspen Neuroscience.
- Learn about the crucial role of optical genome mapping in verifying iPSC genomic integrity for clinical application.
- Explore the impact of OGM in pioneering safe, innovative therapies in regenerative medicine.
Travis Hardcastle: Empowering Therapy Innovation with High-Quality Engineered Cells & Optical Genome Mapping
- Witness Travis Hardcastle’s journey into cell and gene therapy at Synthego, inspired by his family’s battle with Parkinson’s disease.
- See the use case value of Synthego’s innovative engineered cell technologies and their impact on therapy development.
- Unravel the significance of OGM in enhancing Synthego’s cell quality and its breakthroughs.
OVERCOME LIMITATIONS IN CELL & GENE THERAPY
Optical genome mapping overcomes the limitations of conventional techniques for genome integrity assessment.
| Methods | Limitations | Time to Complete |
| Karyotyping |
Low-resolution Highly subjective Unable to detect allelic imbalances High turnaround time Complex workflow requiring specialized staff Requires cell culturing (added 7 – 14 days) |
1-2 weeks in-house 5-8 weeks when outsourced |
| PCR |
Only used for aneuploidy and target sites
Not genome-wide |
<1 week |
| CMA |
Only detects CNVs and allelic imbalances
Cannot detect balanced rearrangements Challenges resolving repeat rich regions |
<1 week |
| NGS |
Targeted sequencing will not detect most CNVs or SVs
Challenges detecting certain genomic variants in heterogeneous populations Rarely genome-wide Genome-wide sequencing is costly and has low sensitivity for CNVs and SVs |
Variable |
Single assay to detect all structural and numerical variants
Unbiased whole genome screening
Simplified workflow
High resolution and sensitivity
Rapid results
Easily implemented and scaled in-house
Advantages of Optical Genome Mapping
 |
Single assay to detect all structural and numerical variants |
 |
Unbiased whole genome screening |
 |
Simplified workflow |
 |
High resolution and sensitivity |
 |
Rapid results |
 |
Easily implemented and scaled in-house |
Reach higher levels of structural variant detection with OGM.
Greater Certainty
Detects all classes of structural variants other methods miss
High Reproducibility
Dependable, reproducible results
No need for duplicate or subsequent testing
High Resolution
Detects structural variants with high sensitivity
High specificity
Unbiased, Genome-Wide Results
Broad and objective view of the genome
See even deeper and rarer variants
Fast Turnaround Time
Results in just 3-5 days
Featured Products of the OGM Workflow
The Stratys™ System delivers comprehensive cell and gene therapy SV detection at scale. With unprecedented flexibility and throughput, Stratys empowers you to achieve deep genomic coverage and move cell and gene therapy programs forward with confidence.
Webinars
See how cell and gene therapy developers are using OGM to streamline genome integrity assessment.
Utilizing Optical Genome Mapping for Cell Line Genomic Integrity and Off-target Characterization
Hear from Dr. Jeanne Loring, Professor Emeritus at the Scripps Research Institute and founding Director of the Center for Regenerative Medicine present on how the utilization of optical genome mapping (OGM) is a revolutionary end-to-end workflow that delivers unparalleled genome-wide structural and numerical variation with powerful objective analysis.
Watch Webinar
The Emerging Role of OGM in Immunotherapy Research – Reveal New Avenues for Genome Assessment in Cell and Gene Therapy Applications: Utilizing OGM for CAR-T Analysis
In this webinar, Dr. Alex Hastie, VP of Clinical and Scientific Affairs at Bionano, will provide an introduction on the utility of OGM in cell and gene therapy. Dr. Rashmi Kanagal-Shamanna, Director of the Molecular Diagnostic Lab at MD Anderson Cancer Center, will then present her lab’s experience using OGM with immunotherapies, focusing on CAR-T therapy.
Watch Webinar
OGM in Cell and Gene Therapy: Symposium Day 4 On-demand
Symposium 2024 day 4 centered around on OGM’s potential to serve as a genomic integrity tool for cell and gene therapy applications, supporting the development of in vivo gene therapies. Six Panelists will cover OGM’s ability to screen cell lines for genomic instability and off-target events associated with genome editing.
Watch WebinarKEY PUBLICATIONS
INTERACTIVE FLIPBOOK
Learn more about OGM for next-level genome integrity assessment.
Connect with a Specialist.
Get in touch to discuss how OGM can benefit your cell and gene therapy program.
Learn More About OGM
Why Structural Variation Matters
Read about what structural variations are and why they matter.
Learn More
The Stratys™ System
Reveal genome-wide structural variation with the Stratys™ Optical genome mapping system.
Learn More